As the European Commission prepares to launch a much awaited revised EU pharmaceutical strategy, two recent studies by the European Parliament's Panel for the Future of Science and Technology (STOA) advance possible options to tackle current weaknesses in drug development and ensure access to high-quality medicines, including the creation of large-scale European biomedical infrastructure, and a series of targeted strategies to improve EU health research coordination and reprioritise areas of unmet therapeutic need.